Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Belatacept Process E vs Process C in Healthy Participants
NCT03375138Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belatacept in kidney transplant rejection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the serum concentration-time curve from time zero extrapolated to infinite time and Maximum observed serum concentration. Started Dec 2017; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03375138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375138.